Opinion|Videos|October 7, 2024
Dravet Syndrome: Comorbidities and Patient Quality of Life
Author(s)M. Scott Perry, MD
Key Takeaways
- Dravet syndrome comorbidities include developmental delays, behavioral issues, sleep disturbances, and increased infection risk, requiring comprehensive management strategies.
- Multidisciplinary management involves pharmacological interventions, behavioral therapies, and supportive care to address the diverse needs of patients.
Scott Perry, MD, discusses how pediatric patients with Dravet syndrome often experience various comorbidities alongside seizures, including developmental delays, behavioral issues, and sleep disturbances, which significantly impact quality of life, especially when diagnosis is delayed, necessitating comprehensive management strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What comorbidities do pediatric patients with Dravet syndrome experience?
- How are these comorbidities managed?
- What is the effect of Dravet syndrome on a patient’s quality of life?
- How does a delayed diagnosis affect a patient's quality of life?
Advertisement
Related to this article
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Givinostat Data Point to Delayed Loss of Ambulation, Preserved Muscle Tissue in DMD
4
Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C
5